PharmaNet Development Group Continues Strategic Global Expansion

PharmaNet Development Group, Inc. (NASDAQ: PDGI), (the "Company”), a leading provider of global drug development services, today announced that it has opened a new Phase I clinic in Toronto, Canada and new offices in Brussels, Belgium and Milan, Italy. In addition, the Company has relocated its Zurich, Switzerland office to allow for future growth of its staff. "In support of the continued growth in demand for clinical development services and the trend towards more large, global studies, we are opening additional office locations and clinics to intensify our presence in the region and meet the needs of our clients around the world,” commented Jeffrey P. Mc Mullen, president and chief executive officer, PharmaNet Development Group, Inc. "We believe this continued expansion will allow us to serve our clients better.” The new clinical facility in Toronto is approximately 40,000 square feet and contains four clinical units that can accommodate a total of 160 beds. The modern facility is centrally located and easily accessible to staff, volunteers and visitors. The clinic will allow for optimal quality and synergies with the Company’s existing clinics located in Québec City and Montreal, Canada. The new offices in Brussels, Milan and Zurich are strategically located to provide support to clients conducting late stage clinical development programs in these regions. Each office includes room for future expansion. The Brussels office, which opened last month, initially houses a staff of five. The Milan office, which opened earlier this month, currently accommodates nine office-based employees and supports a number of field-based regional staff. The new larger location in Zurich currently accommodates twenty-six employees. About PharmaNet Development Group, Inc. PharmaNet Development Group, a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The Company offers clinical-development services including early and late stage consulting, Phase l and bioequivalence clinical studies, bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and more than 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit www.pharmanet.com. Forward-Looking Statements Certain statements made in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, industry trends and information; the Company's ability to determine its impairment charges and costs of discontinued operations; whether the Company will achieve its estimated value relating to the sale of the land (and any other asset) previously used in discontinued operations; developments with respect to the SEC's inquiry and securities class action lawsuits and derivative lawsuits; the Company’s ability to successfully achieve and manage the technical requirements of specialized clinical trial services, while complying with applicable rules and regulations; regulatory changes; changes affecting the clinical research industry; a reduction of outsourcing by pharmaceutical and biotechnology companies; the Company’s ability to compete internationally in attracting clients in order to develop additional business; the Company’s evaluation of its backlog and the potential cancellation of contracts; its ability to retain and recruit new employees; its clients' ability to provide the drugs and medical devices used in its clinical trials; the Company’s future stock price; the Company’s assessment of its effective tax rate and tax allowance; the Company’s financial guidance; the Company’s future effective tax rate; the Company’s anticipated capital expenditures; the Company’s costs associated with compliance of Section 404 of the Sarbanes-Oxley Act; the impact on the Company of foreign currency transaction costs and the effectiveness of any hedging strategies it implements; and the national and international economic climate as it affects drug development operations. Further information can be found in the Company’s risk factors contained in its Annual Report on Form 10-K for the year ended December 31, 2006 and its most recent Quarterly Report on Form 10-Q. The Company does not undertake to update the disclosures made herein, and you are urged to read our filings with the Securities and Exchange Commission.